LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

It is still too early to determine any definitive federal policies for 2025 (or beyond) that could affect these companies. However, some analysts have speculated that the administration might restrict ...

Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...

Johnson & Johnson JNJ, through its Innovative Medicine segment, commercializes multiple blockbuster therapies spanning a wide ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. Pfizer plans to invest $1 billion in China ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I'm back in ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. CHICAGO — Funding cancer research isn't usually a ...

Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to ...

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

(Reuters) - Pfizer Inc and Plc have resumed talks about a trans-Atlantic merger of the two drug giants after Pfizer sweetened the terms of an earlier takeover offer for its British rival, the Wall ...